

Open

Efficacy and Safety of Over-the-Counter Therapies for Chronic Constipation: An Updated Systematic Review

Satish S.C. Rao, MD, PhD¹ and Darren M. Brenner, MD²

INTRODUCTION: Constipation is commonly treated with over-the-counter (OTC) products whose efficacy and safety remain unclear. We performed a systematic review of OTC therapies for chronic constipation and provide evidence-based recommendations.

METHODS: We searched PubMed and Embase for randomized controlled trials of ≥ 4 -week duration that evaluated OTC preparations between 2004 and 2020. Studies were scored using the US Preventive Services Task Force criteria (0–5 scale) including randomization, blinding, and withdrawals. The strengths of evidence were adjudicated within each therapeutic category, and recommendations were graded (A, B, C, D, and I) based on the level of evidence (level I, good; II, fair; or III, poor).

RESULTS: Of 1,297 studies identified, 41 met the inclusion criteria. There was good evidence (grade A recommendation) for the use of the osmotic laxative polyethylene glycol (PEG) and the stimulant senna; moderate evidence (grade B) for psyllium, SupraFiber, magnesium salts, stimulants (bisacodyl and sodium picosulfate), fruit-based laxatives (kiwi, mango, prunes, and ficus), and yogurt with galacto-oligosaccharide/prunes/linseed oil; and insufficient evidence (grade I) for polydextrose, inulin, and fructo-oligosaccharide. Diarrhea, nausea, bloating, and abdominal pain were common adverse events, but no serious adverse events were reported.

DISCUSSION: The spectrum of OTC products has increased and quality of evidence has improved, but methodological issues including variability in study design, primary outcome measures, trial duration, and small sample sizes remain. We found good evidence to recommend polyethylene glycol or senna as first-line laxatives and moderate evidence supporting fiber supplements, fruits, stimulant laxatives, and magnesium-based products. For others, further validation with more rigorously designed studies is warranted.

SUPPLEMENTARY MATERIAL accompanies this paper at <http://links.lww.com/AJG/B929>

Am J Gastroenterol 2021;116:1156–1181. <https://doi.org/10.14309/ajg.000000000001222>

INTRODUCTION

Constipation is a common condition with individual studies reporting prevalence rates ranging from 2% to 39% (1–5). This wide variability seems to be related to both differences in populations studied and the criteria used to define constipation (6–8). One systematic review found that when ROME criteria were applied, prevalence ranged from 6.8% (ROME III) to 15.0% (ROME II), whereas rates of self-reported constipation were generally higher (3). Constipation is more common in women than in men, and its incidence increases with advancing age (2). Constipation has significant clinical, economic, and quality of life (QoL) impacts (4,9) and correlates with significantly higher rates of psychological distress (10). The QoL impact is similar to that of numerous other chronic conditions, including sciatica, dermatitis, and chronic allergies (9).

Approximately 40% of patients with constipation in the United States self-treat with laxatives (11), and in 2019, more than

\$1.5 billion dollars were spent on over-the-counter (OTC) agents (12). A claims-based analysis estimated the cost of gastrointestinal (GI) symptom management in patients with chronic constipation to be \$1,500 per patient per year, inflation adjusted to 2020 dollars (5,13). There are many OTC preparations available to manage constipation, each with a different mechanism(s) of action. However, there is considerable variability in both the quality and quantity of evidence supporting their use. One of the authors (S.R.) previously reviewed the efficacy and safety data for OTC therapies in the management of adult patients with chronic constipation (date range 1966–2004), identifying that many of the treatment options lacked robust supporting evidence (14). Since then, numerous additional products have become available, and new trials have been conducted.

Our objective here was to perform an updated evidence-based systematic review of OTC treatment options for chronic

¹Division of Gastroenterology/Hepatology, Medical College of Georgia, Augusta University, Augusta, Georgia, USA; ²Division of Gastroenterology Northwestern University—Feinberg School of Medicine, Chicago, Illinois, USA. **Correspondence:** Darren M. Brenner, MD. E-mail: Darren-brenner@northwestern.edu.

Received November 7, 2020; accepted February 4, 2021; published online March 17, 2021

constipation. We systematically reviewed new data published over the past 15 years and aimed to update the classification of products and provide new treatment recommendations based on levels and strength of evidence.

METHODS

Literature search

PubMed and Embase were searched from 2004 through July 2020 using the following search terms: (constipation OR opioid-induced constipation) AND (laxatives, stimulant OR laxatives, osmotic OR laxatives, irritant OR laxatives, bulk OR fecal softeners OR stool softener OR sorbitol OR magnesium OR milk of magnesia OR magnesium sulfate OR magnesium sulphate OR bisacodyl OR calcium polycarbophil OR polyethylene glycol OR PEG OR senna OR ispaghula OR bran OR celandin OR docusate OR aloe vera OR alo vera OR poloxalkol OR mineral oil OR glycerin OR glycerine OR psyllium OR methylcellulose OR herbal remedies OR traditional medicine OR Chinese herbal OR plantain OR doxinate OR prune OR kiwi OR fiber OR iberogast OR STW 5 OR sodium picosulfate OR macrogol OR sennosides OR inulin). Limits on the search were English language, randomized clinical trial, adults, and human.

Selection criteria

Abstracts of articles were screened, potentially relevant studies published in full were reviewed, and the following selection criteria were applied for inclusion: (i) randomized controlled trial (placebo or active comparator), (ii) parallel or cross over design, (iii) established definition of constipation (preferably ROME criteria), (iv) minimum duration of 4 weeks of active treatment, and (v) well-defined clinical endpoints. Studies evaluating colonic cleansing before colonoscopy or surgery, acute constipation indications (typically 1–2 days or weeks in duration), and patients with irritable bowel syndrome and/or evacuation disorders were excluded. Certain studies in patients with chronic comorbidities (i.e., chronic kidney disease [CKD]) were included.

Data extraction and analysis

Articles that met inclusion criteria were independently reviewed by both authors, and relevant data were extracted. This included therapeutic and control agent(s), study design, number of patients, mean age or age range, sex, study duration, outcome measures, efficacy, and safety outcomes.

Qualitative assessment of study methodology

Next, each study was independently scored by both authors for quality of evidence using the US Preventive Services Task Force criteria (15). Any discrepancies between authors were reconciled by mutual discussion and a second review of all relevant articles. Final scores were adjudicated by consensus. Individual study quality was determined using a 0- to 5-point scale summing individual scores for randomization, blinding, and completeness of follow-up:

1. Randomization was scored as 1 (simply described as randomized) or 2 (appropriate randomization technique and concealed allocation explicitly described)
2. Blinding was scored as 0 (not blind), 1 (described as double blind but no details provided), or 2 (both subjects and investigators were explicitly said to be blinded, and an identical placebo was used)

3. Withdrawals were scored as 0 (no statement) or 1 (number of withdrawals and reason was stated)

Levels of evidence classification of products and grading of recommendations

Current US Preventive Services Task Force (15) criteria were used to score the strength of evidence and grade recommendations. Once again, each investigator provided independent recommendations, and any differences were resolved by consensus. The level of evidence was graded as good (level I), fair (level II), or poor (level III). The recommendation was graded as A (good evidence in support), B (moderate evidence in support), C (poor evidence in support), D (moderate evidence against), or I (insufficient evidence). These criteria represent a slight modification of the grading criteria used in the previous systematic review (14). Detailed descriptions of the grading criteria and differences in the grading criteria between the previous review and the current review are summarized in Supplemental Table 1 (see Supplementary Digital Content 1, <http://links.lww.com/AJG/B929>).

After applying the selection criteria, we identified 41 studies that are included in this analysis. OTC products were grouped into the following 8 categories: osmotic laxatives, fiber laxatives, stimulant laxatives, magnesium-based laxatives, fruit-based laxative, foods with prebiotics, surfactants, and miscellaneous agents.

RESULTS

Studies

A total of 1,297 studies were identified from the Embase/PubMed literature searches. Of these, 110 were identified as randomized clinical trials evaluating treatments for constipation. Studies outside the selection criteria were excluded. In addition, we decided to limit the results to more readily available agents. Thus, some categories that were included in the search strategy (i.e., Chinese herbals, traditional medications, and probiotics) were not included in the results. Overall, a total of 40 studies were included in the analysis (Figure 1). In addition, a late-breaking study (16) published after our literature search was added, bringing the total number of qualifying studies to 41.

There was considerable variability in the quality of studies, the patient populations who were enrolled, and outcomes evaluated. A comparison of our current recommendations and those previously reported is summarized in Table 1. Study details and results for each product included in this review are summarized in Tables 2–7 and discussed in detail below. Studies that included products from more than one treatment category were included in both tables. Treatment categories are organized according to the quality of evidence, and those with the strongest evidence are discussed first.

Osmotic agents

Osmotic agents draw fluid into the intestine, soften stool, and increase luminal water retention, and the ensuing luminal distention secondarily increases colonic peristalsis and causes laxation (17,18). PEG is an osmotic agent that is approved by the US Food and Drug Administration (US FDA) for the treatment of occasional constipation (19). It is poorly absorbed (<0.28%), and nearly 100% of PEG is excreted in the feces (20). No other osmotic agents meeting current inclusion criteria were identified (magnesium-based laxatives are discussed separately).




Figure 1. Flow diagram of study. ^aOne study added after literature search. ^bThree studies were included in 2 categories.

Nine PEG studies satisfied the selection criteria in this updated analysis (Table 2), with methodological scores of 5 ($n = 3$), 4 ($n = 1$), 3 ($n = 3$), and 2 ($n = 2$). Three were placebo controlled (21–23), one compared PEG with PEG plus electrolytes (24), and 6 compared PEG with another active product. Two studies compared PEG with lactulose (25,26), whereas single studies compared PEG with tegaserod (27), prucalopride (28,29), and naloxegol (30). The 3 placebo-controlled trials were well designed, included large numbers of patients, and had appropriate clinically relevant endpoints. In these studies, PEG formulations demonstrated significantly greater responses versus placebo on primary (mainly ROME-based response criteria) and secondary endpoints following both short- (4 weeks) and long-term administration (6 months) (21–23). PEG preparations also demonstrated significantly greater efficacy across various endpoints compared with tegaserod (27), prucalopride (28,29), and lactulose (25) in patients with ROME-defined constipation. In patients with opioid-induced constipation, patient preferences for PEG were equivalent to naloxegol (30). In a comparative trial, iso-osmotic and hypo-osmotic formulations of PEG demonstrated similar efficacy and safety, indicating that the addition of electrolytes to PEG formulations may not yield significant clinical advantages in the context of constipation (24).

Consistent with their lack of significant systemic absorption and low rates of metabolism, PEG formulations were well tolerated with low incidences of adverse events. Most events were GI and mild to moderate in intensity and included abdominal distension, diarrhea, loose stools, flatulence, and nausea (21,22,24).

Overall, the data support PEG as an effective treatment with minimal side effects. Response rates were superior to psyllium and prescription agents and similar to naloxegol for the treatment of chronic and opioid-induced constipation, respectively. These data confirm

and support PEG as a first-line agent for the treatment of chronic constipation.

PEG: Level I Evidence, Grade A Recommendation

Stimulant agents

Stimulant laxatives can be subdivided into 2 categories: diphenylmethane derivatives (e.g., bisacodyl and sodium picosulfate) and plant-based anthraquinones (e.g., senna, aloe, and cascara). All act locally at the nerve plexus of smooth muscle in the intestine to stimulate colonic motility.

Four trials using diphenylmethane derivatives (Table 3) were identified in the current analysis. Two (1 bisacodyl, 1 sodium picosulfate) were placebo controlled. Both were large, rigorously designed studies (methodological scores = 5), and active treatment with both agents was associated with significant increases in mean complete spontaneous bowel movements (CSBMs)/week (the primary endpoint in both trials) compared with placebo (31,32). In a comparative trial, bisacodyl and sodium picosulfate demonstrated similar efficacy (i.e., number of bowel movements [BMs]/stool consistency) and safety (33). Bisacodyl proved inferior to the cholinesterase inhibitor pyridostigmine in the final study based on BM frequency and a visual analog scale assessing pain on a 0- to 10-point scale (34).

Two studies also evaluated the anthraquinone senna (methodological score = 5; Table 3). In the first, senna was superior to placebo and had similar efficacy to a Chinese herbal preparation used for constipation (MaZiRenWan) as assessed by complete response rates (i.e., increase of ≥ 1 CSBM/week) (35). Senna was also superior to placebo for secondary endpoints, including frequency of CSBMs and spontaneous BM (SBMs), severity of constipation, and sensation of straining. In a recently published study from Asia, senna (at a starting dose of 1 g/d, which could subsequently be reduced) was superior to placebo in improving

Table 1. Comparative, evidence-based recommendations for OTC products in the management of constipation from 1996 to 2004 (14) and 2004–2020 (current review)

OTC products for constipation	Ramkumar/Rao 1966–2004 (14)		Current review 2004–2020	
	Level of evidence	Recommendation grade	Level of evidence	Recommendation grade
Osmotic laxatives				
PEG	I	A	I	A
Stimulants				
Senna	III	C	I	A
Bisacodyl	III	C	I	B
Sodium picosulfate	III	C	I	B
Magnesium				
Magnesium hydroxide	III	C	NA	NA
Magnesium-rich water	NA	NA	I	B
Magnesium oxide	NA	NA	I	B
Fruit-based laxatives and foods with prebiotics				
Kiwi	NA	NA	I	B
Mango	NA	NA	II	B
Ficus	NA	NA	II	B
Prunes	NA	NA	II	B
Rye bread with yogurt	NA	NA	III	C
Yogurt with galacto-oligosaccharide + prunes + linseed oil	NA	NA	II	B
Fiber-containing products				
Soluble fiber				
Psyllium	II	B	II	B
Polydextrose	NA	NA	I	Insufficient
Inulin	NA	NA	I	Insufficient
Insoluble fiber				
Bran, methylcellulose	III	C	NA	NA
Mixed fiber				
SupraFiber	NA	NA	II	B
Miscellaneous ^a				
Polydextrose	NA	NA	II	B
Flaxseed oil	NA	NA	II	C
Fructo-oligosaccharide	NA	NA	III	Insufficient
Surfactants				
Docosate	III	C	NA	NA

NA, not assessed; OTC, over-the-counter; PEG, polyethylene glycol.
^aAssessed in patients with chronic kidney disease.

overall symptoms (primary endpoint), stool frequency, and QoL; however, the doses of senna consumed were significantly greater than those used in clinical practice in the United States (16).

Most adverse events were GI in nature owing to the irritant properties of stimulants. Increased rates of diarrhea (32%–53% vs 2%–5%) and abdominal pain (6%–25% vs 2%–3%) in comparison to placebo may limit the tolerability of bisacodyl (31) and sodium picosulfate (32). Senna was well tolerated in 1 study (35), but in

the more recent study, 83.3% of subjects requested dose reduction of senna because of abdominal pain and diarrhea but completed the 4-week trial (16).

Overall, these data indicate that senna, bisacodyl, and sodium picosulfate are effective for the treatment of chronic constipation, although they are associated with increased potential for dose reduction or intolerance.

Table 2. Osmotic laxatives in the treatment of constipation

Reference	Methodologic score ^a	Intervention	Study design	Patients					Outcomes			
				N	Mean age, yrs	F/M	Diagnosis	Duration	Outcome parameters	Main efficacy results	Safety	
PEG												
PEG vs placebo												
DiPalma et al. (21)	5 (2,2,1)	PEG 3350 17 g vs PBO QD (2:1)	r, db, mc, pc, pg	304	53–54	258/46	Constipation—modified ROME criteria	6 mo	Response ^b (primary); % of pts with ≥50% of treatment wks scored as “successful” on modified ROME; % of wks meeting ROME; super efficacy; individual ROME symptoms	PEG associated with significantly higher response vs PBO: 52% vs 11%, <i>P</i> < 0.001 (primary endpoint); PEG > PBO for 11 of 12 primary and secondary endpoints (<i>P</i> < 0.001)	No safety differences except for GI complaints: PEG 40%, PBO 25%, <i>P</i> = 0.015	
DiPalma et al. (22)	5 (2,2,1)	PEG 3350 17 g vs PBO QD (1:1)	r, db, mc, pc, pg	100	58	74/26	Constipation—ROME II	4 wks	Treatment success ^c (primary), no. of BMs, CBMs, satisfactory BMs	Treatment success significantly higher with PEG vs PBO: 78% vs 39% (<i>P</i> < 0.001); PEG > PBO at 4 wks for BMs (8.1 vs 5.4; <i>P</i> = 0.001), CBMs (6.2 vs 3.7; <i>P</i> = 0.005), satisfactory BMs (5.9 vs 3.6; <i>P</i> = 0.008)	No statistically significant differences in AEs, including GI complaints (32% vs 20%; <i>P</i> = 0.254)	
Zangaglia et al. (23)	4 (1,2,1)	PEG 4000 + E 7.3 g vs PBO BID (1:1)	r, db, mc, pg	57	71	23/34	Constipation—ROME II and Parkinson disease	8 wks	Response ^d SF, SC, straining	Response greater for PEG 4000 + E at wk 4 (78% vs 25%; <i>P</i> = 0.0003) and wk 8 (80% vs 30%; <i>P</i> = 0.0012). SF increased significantly more than PBO at wk 4 (5.7 vs 3.4) and wk 8 (6.6 vs 3.7; <i>P</i> < 0.002 for both)	Higher rate of withdrawals with PEG 4000 + E vs PBO (31% vs 18%)	
PEG vs tegaserod												
DiPalma et al. (27)	3 (2,0,1)	PEG 3350 17 g QD vs tegaserod 6 mg BID (1:1)	r, ol, mc, pg	239	46	213/24	Constipation—modified ROME criteria	4 wks	Response ^b (primary); no. of wks meeting primary definition; no. of wks meeting ROME definition; no. of wks with complete response ^e ; individual ROME symptoms; BM frequency, satisfactory BMs, CSBMs	PEG associated with significantly higher response vs tegaserod: 50% vs 31%, <i>P</i> = 0.003 (primary endpoint); PEG > tegaserod for many secondary endpoints including meeting: Primary definition (<i>P</i> = 0.003), ROME definition (<i>P</i> = 0.006), complete response (<i>P</i> = 0.028)	No differences in AEs except for more headache in tegaserod group (6% vs 0%)	

Table 2. (continued)

Reference	Methodologic score ^a	Intervention	Study design	Patients				Outcomes			
				N	Mean age, yrs	F/M	Diagnosis	Duration	Outcome parameters	Main efficacy results	Safety
PEG vs PEG + E											
Seinela et al. (24)	3 (1,1,1)	PEG 4000 12 g vs PEG 4000 + E 12 g QD, BID, or QOD (1:1)	r, db, mc, pg	62	85–86	41/21	Constipation, elderly, institutionalized	4 wks	SF (primary), SC, straining	Mean weekly SF similar between PEG 4000 and PEG 4000 + E at wk 2 (9.5 vs 8.7) and wk 4 (8.5 vs 8.4 [primary endpoint]); % of patients with soft/normal SC was not significantly different at wk 2 (59% vs 38%) and wk 4 (70% vs 52%); No difference in straining	Overall rate of AE low and not significantly different; most common events in PEG 4000 and PEG 4000 + E: flatulence (24% vs 40%), abdominal pain (21% vs 17%), bloating (14% vs 10%), and nausea (3% vs 10%)
PEG vs prucalopride											
Cinca et al. (28,29)	5 (2,2,1)	PEG 3350 + E 13 g BID vs prucalopride 1–2 mg QD (1:1)	r, db, pg	240	40–41	240/0	CC—ROME III criteria	4 wks	≥3 CSBMs in last treatment wk (primary), mean weekly CSBMs, CTT	≥3 CSBMs in last treatment wk higher for PEG 3350 + E than for prucalopride (66.7% vs 56.5%; rate difference 10.1% with 97.5% lower CI limit, –2.7% above preset margin of –20%); Mean weekly CSBMs significantly higher with PEG 3350 + E during each wk (13.1 vs 9.0; <i>P</i> < 0.001)	Most frequent AEs occurred less often with PEG 3350 + E: headache (37% vs 55%); dysmenorrhea (13% vs 16%); nausea (6% vs 13%); pharyngitis (6% vs 11%)
PEG vs naloxegol											
Brenner et al. (30)	2 (1,0,1)	PEG 3350 17 g QD vs naloxegol 25 mg QD (1:1)	r, mc, co, ol	270	56	176/94	OIC—ROME-IV	6 wks	Secondary endpoints: Change in BFI and PGIC	Similar change from baseline in BFI and PGIC for both treatment groups	PEG vs naloxegol: GI AEs 10.8% vs 16.2%; nervous system AEs 0% vs 4.4%

Table 2. (continued)

Reference	Methodologic score ^a	Intervention	Study design	Patients					Outcomes		
				N	Mean age, yrs	F/M	Diagnosis	Duration	Outcome parameters	Main efficacy results	Safety
PEG vs lactulose											
Chassagne et al. (25)	3 (2,0,1)	PEG 4000 10 g QD to TID vs lactulose 10 g QD to TID (1:1)	r, mc, sb, pg	245	82	186/59	CC—ROME I	6 mo	SF, SC, fecaloma, fecal incontinence, sensation of rectal emptying, difficulty passing stool, and meteorism rescue medication	SF significantly higher with PEG 400 vs lactulose from month 2 onward (7.0–7.3/wk vs 5.5–6.2/wk); PEG associated with significantly improved SC ($P < 0.05$) and less rescue treatment ($P = 0.004$); Other endpoints generally similar between treatments	No difference in overall pattern of AEs between groups; PEG 4,000 vs lactulose: Total AEs 57% vs 50%; diarrhea 9% vs 9%; abdominal pain 8% vs 4%
Piche and Dapoigny (26)	3 (2, 0, 1)	PEG 3350 13.125 g vs lactulose 3.5 g + paraffin 4.29 g QD (1:1)	r, mc, sb, pg	363	53	263/100	CC—ROME III	4 wks	PAC-SYM (primary); PAC-QOL SBMs, SC	PAC-SYM significantly decreased from baseline in both groups (2.1–0.9 for both) with noninferiority between groups. Similar improvements in SBMs, SC, and PAC-QOL	AEs were similar in PEG (14.2%) and lactulose/paraffin group (11.2%); primarily mild-to-moderate GI AEs

AE, adverse event; BFI, Bowel Function Index; BID, twice daily; BM, bowel movement; CBM, complete bowel movement; CC, chronic constipation; CI, confidence interval; co, cross-over; CSBM, complete spontaneous bowel movement; CTT, colonic transit time; db, double blind; E, electrolytes; GI, gastrointestinal; F/M, female/male; mc, multicenter; OIC, opioid-induced constipation; ol, open label; PBO, placebo; pc, placebo controlled; PAC-QOL, Patient Assessment of Constipation-Quality of Life; PAC-SYM, Patient Assessment of Constipation Symptom; PEG, polyethylene glycol; pg, parallel group; PGIC, Patient Global Impression of Change; pts, patients; QD, once daily; QOD, every other day; r, randomized; sb, single blind; SBM, spontaneous bowel movement; SC, stool consistency; SF, stool frequency; TID = 3 times daily.

^aTotal methodologic score with individual scores for randomization, blinding, and statement on withdrawals shown in parentheses.

^bWeekly treatment success (response), defined as meeting all 3 elements: (i) no rescue laxative; (ii) satisfactory stool ≥ 3 time/wk; (iii) ≤ 1 of remaining ROME-based symptom criteria (straining in $>25\%$ of defecations; lumpy/hard stool in $>25\%$ of defecations; sensation of incomplete evacuations in $>25\%$ of defecations).

^cSuccess defined as ≤ 1 of ROME-based symptom criteria (straining in $>25\%$ of defecations; lumpy/hard stool in $>25\%$ of defecations; sensation of incomplete evacuations in $>25\%$ of defecations; sensation of anorectal obstruction/pageage in $>25\%$ of defecations; <3 bowel movements per wk).

^dResponse defined as complete relief or a marked improvement of the predominant symptom and ≥ 1 associated symptom or sign (e.g., SF, SC, straining, rescue therapy).

^eNo ROME symptom criteria met.

Senna: Level I Evidence, Grade A Recommendation
Bisacodyl: Level I Evidence, Grade B Recommendation
Sodium Picosulfate: Level I Evidence, Grade B Recommendation

Magnesium-containing agents

Magnesium-based compounds are laxatives that act by retaining water in the intestinal lumen, resulting in bulking and softening of stool (36). Magnesium salts have historically been classified as osmotic, saline, or mixed osmotic-saline laxatives with categorization dependent on the magnesium compound used. Although magnesium citrate is a stronger formulation with more characteristically osmotic properties, other agents including magnesium hydroxide, magnesium gluconate, and magnesium oxide or magnesium enriched water act as more gentle saline laxatives. Given the breadth of new studies evaluating different magnesium-based formulations, these results have been categorized and addressed separately from the other osmotic agents. This review identified 4 new relevant studies using magnesium-based regimens, 3 evaluating magnesium-rich water vs placebo (Table 4) with methodological scores of 5 (n = 2) and 4 (n = 1) and one evaluating magnesium oxide versus placebo or senna (16). The amount of elemental magnesium consumed in the 3 magnesium water studies varied from 105 mg/d (1,000 mL/d of water containing 105 mg/L Mg) (37), 60 or 119 mg/d (500 or 1,000 mL/d of water containing 119 mg/L Mg) (38) to 500 mg/d (500 mL/d of water containing 1,000 mg/L of Mg) (39). None of the trials demonstrated a statistically significant difference versus placebo for their primary endpoints (based on stool frequency per week or ROME II-based response), although various secondary endpoints, including stool frequency at alternative time points and stool consistency, were significantly improved (37–39). Magnesium-containing mineral water preparations were well tolerated with low rates of adverse events (diarrhea and abdominal distention). In the magnesium oxide study, subjects were administered a total of 1.5 g in 3 divided doses and reported significant overall improvements in constipation, SBMs, CSBMs, and QoL when compared with placebo but no differences compared with senna (16). Although not explicitly stated, abdominal pain and diarrhea were adverse events, necessitating a dose reduction in 53.3% of subjects. None of the studies reported hypermagnesemia as a potential adverse event.

Magnesium-containing Agents: Level I Evidence, Grade B Recommendation

Fruit-based laxatives

Fruits contain varying proportions of soluble and insoluble dietary fiber (including nonfermentable, slowly fermentable, and rapidly fermentable fibers), sugars (e.g., fructose and sucrose), and sorbitol (40). Fruit-based laxatives increase intestinal water retention and colonic volume, resulting in increased stool frequency and softer stools (41). In this updated review, 5 studies were identified (Table 5). These trials evaluated preparations of kiwi (n = 2), mango (n = 1), ficus (n = 1), and prune (n = 1). The methodological scores of these studies were 5 (n = 3), 3 (n = 1), and 2 (n = 1).

In a small study (N = 9), a kiwi fruit-based supplement had no significant effect on stool frequency or stool consistency versus placebo (42), although a second larger study (N = 87) found that a kiwi-derived powder was associated with significant improvements in the frequency of CSBMs, SBMs, and stool consistency

compared with placebo-treated patients (43). Prunes were associated with significantly greater improvements in mean CSBMs per week (primary outcome) and stool consistency compared with psyllium in 40 patients with chronic constipation (44). A mango-based supplement was associated with significantly improved evacuation categorization (based on stool consistency and shape) compared with psyllium in a pilot study in 36 patients with chronic constipation (45). A *ficus carica* paste significantly improved colonic transit time (primary endpoint), stool consistency, and abdominal discomfort but had no effect on stool frequency, defecation time, abdominal pain, effort for evacuation, and sensation of incomplete evacuation (46).

Fruit-based laxatives were very well tolerated with few (mild GI-related events) or no adverse events reported. Based on the small numbers of patients enrolled in these trials, the data suggest that fruit-based laxatives are a well-tolerated and promising option for the treatment of constipation. Additional well-designed trials are required to confirm their efficacy.

Kiwi-based Laxatives: Level I Evidence, Grade B Recommendation

Mango-based Laxatives: Level II Evidence, Grade B Recommendation

Ficus-based Laxatives: Level II Evidence, Grade B Recommendation

Prune-based Laxatives: Level II Evidence, Grade B Recommendation

Foods with prebiotics

Prebiotics are nondigestible fibers (oligosaccharides such as oligofructose, galacto-oligosaccharides, inulin, and lactulose) that are fermented by and support the growth of beneficial intestinal bacteria (e.g., bifidobacteria and lactobacillus) (47). It is hypothesized that intestinal microbiota increase colonic peristalsis via a number of potential mechanisms and that prebiotics augment this process by supporting a healthy microbiome (48).

Two studies are included in the current analysis. One study (methodologic score = 5) found that a yogurt containing galacto-oligosaccharides, prunes, and linseed oil was associated with significantly greater stool frequency, easier defecation, and softer stools compared with a control yogurt in elderly patients with mild constipation (Table 5) (49). Another study (methodologic score = 2) evaluated rye bread, with or without *Lactobacillus* GG-containing yogurt versus yogurt alone and control (low-fiber toast) in patients with self-reported constipation (50). The rye bread-containing groups experienced shortened intestinal transit time, increased stool frequency, softened stool, and easier defecation compared with low-fiber toast but were associated with increased GI side effects (flatulence and bloating) (50).

Yogurt with Galacto-Oligosaccharides + Prune + Linseed Oil: Level II Evidence, Grade B Recommendation

Rye Bread with Yogurt: Level III Evidence, Grade C Recommendation

Fiber-containing agents

Fiber laxatives work by increasing the weight and water-absorbent properties of stool, thereby increasing stool bulk and

Table 3. Stimulant laxatives in the treatment of constipation

Reference	Methodologic score ^a	Intervention	Study design	Patients					Outcomes			
				N	Mean age, yrs	F/M	Diagnosis	Duration	Outcome parameters	Main efficacy results	Safety	
Stimulant laxatives												
Bisacodyl vs placebo												
Kamm et al. (31)	5 (2,2,1)	Bisacodyl 10 mg vs PBO QD (2:1)	r, db, mc, pg	368	55	275/93	CC, Rome III	4 wks	CSBMs (primary), SBMs, constipation-related symptoms	Mean no. of CSBMs/wk were significantly higher with bisacodyl vs PBO (5.2 vs 1.9; <i>P</i> < 0.0001); SBMs significantly greater with bisacodyl vs PBO (10.0 vs 5.1; <i>P</i> < 0.0001).	Diarrhea (53% vs 2%) and abdominal pain (25% vs 3%) more common with bisacodyl	
Bisacodyl vs Na picosulfate												
Kienzle-Horn et al. (33)	2 (1,0,1)	Bisacodyl 5–10 mg QD vs Na picosulfate 5–10 mg QD (1:1)	r, ol, mc, pg	144	62–64	104/40	CC (<3 BMs/wk × 6 mo)	4 wks	SF, SC (co-primary)	No significant difference between bisacodyl and Na picosulfate for SF per day (1.06 vs 1.11) and SC score (2.43 vs 2.51 at 28 d); Both treatments produced significant improvements in SF and SC vs baseline	No significant difference in no. or severity of AEs; Most common AE in bisacodyl and Na picosulfate groups: Flatulence (7% vs 10%), headache (9% vs 7%), abdominal pain (7% vs 7%)	
Na picosulfate vs placebo												
Mueller-Lissner et al. (32)	5 (2,2,1)	Na picosulfate 10 mg QD vs PBO QD (2:1)	r, db, mc, pg	367	50–52	285/82	CC, Rome III	4 wks	CSBMs (primary), SBMs, constipation-related symptoms	Mean no. of CSBMs per wk significantly higher with Na picosulfate vs PBO (3.4 vs 1.7; <i>P</i> < 0.001). Change in CSBMs, per wk (66% vs 32%); % with ≥3 CSBMs per wk (51% vs	Diarrhea (32% vs 5%) and abdominal pain (6% vs 2%) greater with Na picosulfate vs PBO	

Table 3. (continued)

Reference	Methodologic score ^a	Intervention	Study design	Patients					Outcomes		
				N	Mean age, yrs	F/M	Diagnosis	Duration	Outcome parameters	Main efficacy results	Safety
Bisacodyl vs pyridostigmine											
Soufi-Afshar et al. (34)	3 (1,1,1)	Bisacodyl 5 mg TID vs pyridostigmine 60 mg TID (1:1)	r, db	68	50	40/28	CC—Rome III	4 wks	BMs, VAS	18%), and % with ≥1 CSBMs/day (10% vs 0%) all significantly greater with Napicosulfate (<i>P</i> < 0.001 for all)	Not reported
Herbal stimulant laxatives											
Senna vs MaZiRenWan vs placebo											
Zhong et al. (35)	5 (2,2,1)	Senna 15 mg QD vs MaZiRenWan 7.5 g BID vs PBO (1:1:1)	r, db, mc, pc	291	45	263/28	FC—ROME III	8 wks + 8 wks follow-up	Complete response (increase of ≥1 CSBMs/wk [primary]); colonic transit; symptoms; QoL (SF-36)	Senna and MaZiRenWan both associated with significantly greater complete response vs PBO (58%, 33%; <i>P</i> < 0.005 for both); Senna significantly superior to PBO for severity of constipation, straining, and bloating	All treatments well tolerated with no serious AEs; no significant differences between groups for renal and liver function

Table 3. (continued)

Reference	Methodologic score ^a	Intervention	Study design	Patients					Outcomes		
				N	Mean age, yrs	F/M	Diagnosis	Duration	Outcome parameters	Main efficacy results	Safety
Morishita et al. (16)	5 (2,2,1)	Senna 1 g/d vs Mg oxide 1.5 g/d vs PBO (1:1:1)	r, db, pc, pg	90	42	84/6	CC, ROME IV	4 wks	Response (primary; defined as score of 1 or 2 on 5-point scale), SBM, CSBM, BSFS, and QoL	Response rates with both senna (69.2%) and Mg oxide (68.3%) were both significantly higher ($P < 0.0001$) vs placebo (11.7%); By wk 4, increases in weekly average SBMs, CSBMs, BSFS scores, and QoL scores were significantly higher with senna and Mg oxide vs placebo	No severe symptoms were noted, although dose reductions occurred in 83.3%, 53.3%, and 50% of senna, Mg oxide, and PBO groups ($P = 0.02$ senna vs PBO). No patients dropped out of the study

AE, adverse event; BID, twice daily; BM, bowel movement; BSFS, Bristol Stool Form Scale; CC, chronic constipation; CSBM, complete spontaneous bowel movement; db, double blind; FC, functional constipation; F/M, female/male; mc, multicenter; ol, open label; PBO, placebo; pc, placebo controlled; pg, parallel group; QD, once daily; QoL, quality of life; r, randomized; SBM, spontaneous bowel movement; SC, stool consistency; SF, stool frequency; SF-36, Short Form-36 health survey; TID, 3 times daily; VAS, visual analog scale.

^aTotal score with individual scores for randomization, blinding, and statement on withdrawals in parentheses.

softening stool consistency. Fiber products can be classified based on solubility (soluble vs insoluble), viscosity (viscous vs nonviscous), and fermentability (fermentable vs nonfermentable) (40). Soluble fiber (e.g., psyllium, gums, and pectins) blends with water, forming a gel-like substance, whereas insoluble fiber (e.g., cellulose, lignin, and oligosaccharides) remains unchanged as it passes through the GI tract. Fermentable fibers such as gums, inulin, oligosaccharides, and wheat dextrin can be digested by gut bacteria.

Soluble and mixed fibers. Psyllium (also known as ispaghula) is a soluble fiber derivative of the husk of *Plantago ovata*. We identified 9 new studies that evaluated psyllium (Table 6), with methodological scores of 5 (n = 2), 3 (n = 4), 2 (n = 2), and 1 (n = 1). The doses of psyllium varied substantially in these studies, ranging from 3.5 g/d to 11 g twice daily. Three studies included a placebo arm, and 7 studies included an active comparator (lactitol, flaxseed oil, sodium bicarbonate suppository, lactulose, prunes, mango, and mixed fiber [n = 1 each]). Whereas some studies used an active comparator, in 2 placebo-controlled studies, no differences between psyllium and placebo in global constipation symptom scores were identified, but more patients receiving psyllium had a greater than 2-point symptom improvement from baseline (5-point Likert scale) (51–53). Psyllium was also associated with improved stool consistency at various time points. In the third placebo-controlled trial, which also included lactitol and psyllium + lactitol as comparators, there were no significant differences between any of the 4 groups in terms of stool frequency (primary endpoint), stool

consistency, QoL, or patient-assessed symptoms in subjects with self-reported constipation (<3 BMs/week) (54). In other comparative trials, lactulose (55), mango (45), and prunes (44) significantly outperformed psyllium in stool frequency and consistency.

Two placebo-controlled trials evaluated inulin (56,57), receiving methodological scores of 5 and 4, respectively. In the first study, inulin was associated with increased stool frequency but showed no differences in stool consistency or straining compared with placebo (56). In the second study, no differences in stool frequency or consistency were detected between the inulin and placebo cohorts. Inulin was associated with increased numbers of patients achieving >1 BM/day and fewer defecation difficulties (not defined) compared with baseline (57).

Two placebo-controlled trials (methodological scores = 5) evaluated the potential for polydextrose to improve GI transit time. In both studies, polydextrose proved no more effective than placebo (58,59). One study did identify an increase in SBM frequency (59), but this response was not corroborated by the second (58).

One study (methodological score = 5) compared mixed fiber (plum-derived soluble/insoluble fiber) with psyllium over 4 weeks. Within-group comparisons from baseline identified increased mean numbers of CSBMs per week (primary endpoint), improved stool consistency, and reduced straining but no significant differences between the groups. Mixed fiber was associated with a significantly greater improvement in flatulence compared with psyllium (60).

Table 4. Magnesium-based laxatives in the treatment of constipation

Reference	Methodologic score ^a	Intervention	Study design	Patients					Outcomes		
				N	Mean age, yrs	F/M	Diagnosis	Duration	Outcome parameters	Main efficacy results	Safety
Mg-rich mineral water vs placebo											
Bothe et al. (39)	4 (1,2,1)	MgSO ₄ -rich mineral water (500 mg Mg/d) vs PBO	r, db, pc, pg	75 of 106	46	63/12	CC, ROME III	6 wks	CSBMs (primary), BMs, SBMs, CBMs, and SC	Trend toward more CSBMs/wk for MW vs PBO at 6 wks (2.16 vs 1.16; <i>P</i> = 0.054); SBMs/BMs/wk significantly higher with MW vs PBO at wk 6 (6.62 vs 4.47 <i>P</i> = 0.01); SC improved more for MW vs PBO (<i>P</i> < 0.001)	No difference in AEs between treatment groups
Dupont et al. (38)	5 (2,2,1)	MgSO ₄ -rich MW (low dose [60 mg Mg/d] or high dose [120 mg Mg/d]) vs control water	r, db, mc, pc	244	41–44	244/0	CC, ROME III	4 wks	Response during wk 1 (primary) ^b , response at wks 2, 4; SC, individual and total Rome III diagnostic criteria; abdominal pain, CGIC, PGIC, QoL, rescue medication	Response at wk 1 (33% [low-dose], 34% [high-dose], vs 25% [PBO]) not significantly different (<i>P</i> = 0.099); Response at wk 2 and 4 for MW high-dose group vs PBO (38% vs 21%; <i>P</i> = 0.013 and 39% vs 24%; <i>P</i> = 0.028); SC significantly higher in MW high-dose vs PBO	Similar rates of AEs with MW (n = 15) and PBO (n = 13)
Naumann et al. (37)	5 (2,2,1)	Ca/Mg SO ₄ -rich MW QID (105 mg Mg/d) vs PBO QID	r, db, pc	100	45	85/15	CC, ROME III	6 wks	Change in SF at 6 wks (primary); SF at 3 wks; change in SF per wk; SC, GIQLI, SF-12	Change in SF at wk 6 not significantly different with MW vs PBO (1.74 vs 1.22; <i>P</i> = 0.163); Change in SF at wk 3 significantly greater for MW vs PBO (2.02 vs 0.88; <i>P</i> = 0.005); Significantly greater SF per wk (4.8 vs 3.8; <i>P</i> = 0.036) and stool consistency (3.1 vs 2.7; <i>P</i> = 0.044) for MW vs PBO at wk 3	10 minor to moderate AEs reported (not specified)

Table 4. (continued)

Reference	Methodologic score ^a	Intervention			Patients			Outcomes		
		Study design	Mean age, yrs	F/M	Diagnosis	Duration	Outcome parameters	Main efficacy results	Safety	
Morishita et al. (16)	5 (2,2,1)	r, db, pc, pg	42	84/6	CC, ROME IV	4 wks	Response (primary; defined as score of 1 or 2 on 5-point scale), SBM, CSBM, BSFS, and QoL	Response rates with both senna (69.2%) and Mg oxide (68.3%) were both significantly higher ($P < 0.0001$) vs placebo (11.7%); senna, Mg oxide, and PBO By wk 4, increases in weekly average SBMs, CSBMs, BSFS scores, and QoL scores were significantly higher with senna and Mg oxide vs placebo	No severe symptoms were noted, although dose reductions occurred in 83.3%, 53.3%, and 50% of senna, Mg oxide, and PBO groups ($P = 0.02$ senna vs PBO). No patients dropped out of the study	

AE, adverse event; BM, bowel movement; BSFS, Bristol Stool Form Scale; CBM, complete bowel movement; CC, chronic constipation; CGIC, Clinician's Global Impression of Change; CSBM, complete spontaneous bowel movement; db, double blind; F/M, female/male; GIQLI, Gastrointestinal Quality of Life Index; mc, multicenter; MW, mineral water; PBO, placebo; pc, placebo controlled; pg, parallel group; PGIC, Patient's Global Impression of Change; QID, 4 times daily; QoL, quality of life; r, randomized; SBM, spontaneous bowel movement; SC, stool consistency; SF, stool frequency; SF-12, Short Form Health Survey-12.

^aTotal score with individual scores for randomization, blinding, and statement on withdrawals in parentheses.

^bResponse defined as ≥ 4 stools per wk or an increase of ≥ 2 stools per wk vs baseline and $< 25\%$ lumpy/hard stools.

Soluble fibers (psyllium, inulin, and polydextrose) seem safe and well tolerated. Abdominal distension/pain and flatulence were the most common adverse events and were mild to moderate in nature.

Overall, considering the differences in products tested, dosages used, and variability in study design, the current data suggest that both soluble fiber, psyllium, and mixed fiber (SupraFiber) have modest efficacy for treating constipation. The data are most robust for psyllium. However, it is worth noting that the highest graded placebo-controlled psyllium study (54) revealed no significant benefit over placebo and head-to-head trials revealed that psyllium is less effective than comparator agents (e.g., PEG, lactulose, and fruits).

Psyllium: Level II Evidence, Grade B Recommendation
Polydextrose: Level I Evidence, Grade I (Insufficient) Recommendation
Inulin: Level I Evidence, Grade I (Insufficient) Recommendation
Mixed Fiber: Level II Evidence, Grade B Recommendation

Miscellaneous agents

Table 7 summarizes studies evaluating miscellaneous patient groups and therapeutic agents. Three high-quality studies evaluated constipated patients with CKD (methodological scores of 5 [n = 2] or 4 [n = 1]) (61–63). Polydextrose (61) and fructo-oligosaccharide (63) both demonstrated significant increases in stool frequency versus placebo. In another study, flaxseed oil, olive oil, and mineral oil (control) all significantly reduced the frequency of symptom scores (ROME criteria) from baseline (62).

In other studies evaluating miscellaneous synbiotics or prebiotics, a combination synbiotic of psyllium, inulin, and probiotics significantly increased stool frequency versus baseline at weeks 1 and 2 (but not weeks 3 or 4) and had no effect on stool consistency (64). A prebiotic combination of inulin, lactitol, and aloe vera had no significant benefit for any outcome parameter (19).

Polydextrose: Level II Evidence, Grade B Recommendation (patients with CKD)
Flaxseed Oil: Level II Evidence, Grade C Recommendation (patients with CKD)
Fructo-Oligosaccharide: Level III Evidence, Grade I (Insufficient) Recommendation (patients with CKD)

Surfactants

Docusate is an anionic surfactant that is purported to lower the surface tension at the oil–water interface of stools, allowing water and lipids to penetrate, thereby hydrating and softening stool. Although docusate is one of the most commonly used OTC agents for the treatment of constipation, inconsistent clinical data have led to questions regarding its efficacy. There have been no additional studies since 2004 that met the inclusion criteria for this new analysis. We conclude that despite docusate's frequent use in constipated patients, there is little clinical evidence to support its use.

Surfactants: Level III Evidence, Grade I (Insufficient) Recommendation

DISCUSSION

We have systematically reviewed new evidence supporting the use of OTC laxatives because the previous review was published in 2005. In the previous review, PEG had level I evidence and a

Table 5. Fruit-based laxatives and foods with prebiotics in the treatment of constipation

Reference	Methodologic score ^a	Intervention	Study design	Patients				Duration	Outcomes		
				N	Mean age, yrs	F/M	Diagnosis		Outcome parameters	Main efficacy results	Safety
Fruit-based laxatives											
Kiwi vs placebo											
Ansell et al. (42)	5 (2,2,1)	Kiwi powder (Actazine-L [®] [600 mg/d], Actazine-H [®] [2,400 mg/d], Gold [®] [2,400 mg/d]) vs PBO	r, db, pc, co	9	44	8/1	Constipation—ROME III	4 wks × 4	SF, Bristol scale, symptoms	No significant differences between interventions for BMs, Bristol stool scale	Well tolerated with no significant AE reported
Udani et al. (43)	5 (2,2,1)	Kivia powder 5.5 g QD vs PBO 5.5 g QD (1:1)	r, db, pc, pg	87	38–41	55/32	Occasional constipation (ROME)	4 wks	SF (primary), SC, urgency, bloating discomfort, satisfaction, flatulence, burping	Kivia associated with significant improvements in SBMs and CSBMs at weeks 1, 2, 3, and 4; SC significantly improved with Kivia; Significant improvements for Kivia vs PBO for flatulence, burping, urgency; no difference for bloating or satisfaction	AE: Kivia (n = 7); PBO (n = 1); included flatulence, and bloating
Mango vs psyllium											
Venancio et al. (45)	2 (1,0,1)	Mango 300 g/d vs psyllium 5.8 g/d (1:1)	r	36	24–29	25/11	CC—ROME III	4 wks	Evacuation (primary; difference from ideal [Bristol score = 4]; Agachan score)	Mango significantly improved evacuation category vs psyllium (<i>P</i> = 0.0269); No significant difference for Agachan score; Individual Agachan improved from baseline; Evacuation improved from baseline for mango	No AEs occurred

Table 5. (continued)

Reference	Methodologic score ^a	Intervention	Study design	Patients				Duration	Outcomes		
				N	Mean age, yrs	F/M	Diagnosis		Outcome parameters	Main efficacy results	Safety
Ficus vs placebo											
Baek et al. (46)	5 (2,2,1)	<i>Ficus carica</i> paste 100 mg TID vs PBO TID (1:1)	r, db, pc	80	24	71/9	FC—ROME III	8 wks	CTT (primary); constipation-related symptoms; SC	CTT significantly improved with <i>F. carica</i> vs PBO ($P = 0.045$); <i>F. carica</i> associated with significant effects on SC ($P = 0.024$) and abdominal discomfort ($P = 0.012$) vs PBO but not other symptoms	Safety assessments reported within normal range; no AE-related withdrawals
Prunes vs psyllium											
Attaluri et al. (44)	3 (2,0,1)	Prunes 50 g BID vs psyllium 11 g BID (1:1)	r, sb, co	40	38	NR	CC—ROME III	3 wks × 2	CSBMs (primary), global constipation symptom score, SC, straining	Mean CSBMs/week significantly higher with prune vs psyllium (3.5 vs 2.8; $P = 0.006$); Stool consistency score higher with prune (3.2 vs 2.8; $P = 0.02$); Mean straining scores were similar between treatment groups	Palatability, satiety, postprandial fullness, and bloating were similar

Table 5. (continued)

Reference	Methodologic score ^a	Intervention	Study design	Patients				Duration	Outcomes		
				N	Mean age, yrs	F/M	Diagnosis		Outcome parameters	Main efficacy results	Safety
Foods with prebiotics											
Yogurt containing GOS, prunes, and linseed oil vs control yogurt											
Sairanen et al. (49)	5 (2,2,1)	Active yogurt 130 g BID vs control yogurt 130 g BID	r, db, co	43	76	32/11	>60 yrs, mild constipation	3 wks × 2	SF, SC, symptoms, difficulty with defecation	SF significantly higher with active yogurt (8.0 vs 7.1/wk; <i>P</i> = 0.011); Defecation easier with active yogurt (<i>P</i> = 0.010); Overall GI symptoms did not differ between groups but abdominal pain significantly lower with active yogurt (<i>P</i> = 0.031); active yogurt rated more effective (<i>P</i> = 0.005)	AE not reported
Rye bread vs yogurt vs rye bread + yogurt vs control											
Hongisto et al. (50)	2 (1,0,1)	Rye bread (39 g fiber/day) vs yogurt vs rye bread + yogurt vs control (low-fiber toast [4.5 g/fiber/day]; 1:1:1:1)	r, 2 × 2	59	41	59/0	Self-reported constipation	1 week baseline; 3 wks intervention; 3 wks follow-up	TITT, SF, SC, difficulty of defecation	Rye bread groups associated with higher SF (<i>P</i> = 0.001), easier defecation (<i>P</i> < 0.001) vs low fiber toast; Rye bread associated with significantly shorter TITT vs control (<i>P</i> = 0.007)	GI symptoms increase with rye bread (flatulence, bloating) vs low-fiber toast (<i>P</i> < 0.001); yogurt lowered GI symptoms (<i>P</i> = 0.05)

AE, adverse event; BID, twice daily; BM, bowel movement; CC, chronic constipation; co, crossover; CSBM, complete spontaneous bowel movement; CTT, colonic transit time; db, double blind; FC, functional constipation; F/M, female/male; GI, gastrointestinal; GOS, galacto-oligosaccharides; NR, not reported; PBO, placebo; pc, placebo controlled; pg, parallel group; QD, once daily; r, randomized; sb, single blind; SBM, spontaneous bowel movement; SC, stool consistency; SF, stool frequency; TID, 3 times daily; TITT, total intestinal transit time.

^aTotal score with individual scores for randomization, blinding, and statement on withdrawals in parentheses.

Table 6. Fiber laxatives in the treatment of constipation

Reference	Methodologic score ^a	Intervention	Study design	Patients					Outcomes		
				N	Mean age, yrs	F/M	Diagnosis	Duration	Outcome parameters	Main efficacy results	Safety
Soluble and mixed fibers											
Psyllium vs placebo											
Cheng et al. (54)	5 (2,2,1)	Psyllium 3.5 g vs lactitol 10 g vs psyllium + lactitol vs PBO QD (1:1:1:1)	r, db, pc	172	40	92/80	Constipation—ROME III	4 wks	SF (primary), SC, QoL	No significant increase in SF from baseline for any treatment; No significant difference between any of the 4 treatment groups for all endpoints	AEs reported in 5%, most commonly mild/moderate GI events
Soltanian et al. (51)	3 (2,0,1)	Psyllium 10 g BID vs flaxseed oil 10 g BID vs PBO BID (1:1:1)	r, sb, pc	77	56–58	64/13	Constipation—ROME III and T2DM	12 wks	Symptom score, SF, SC	Flaxseed, but not psyllium associated with improved symptom score vs baseline ($P < 0.001$); Psyllium and flaxseed associated with improved SC vs PBO	Well tolerated with no serious AEs
Soltanian et al. (52)	3 (2,0,1)	Psyllium 10 g BID vs PBO BID (1:1)	r, sb, pc, pg	51	56–58	42/9	Constipation—ROME III and T2DM	12 wks	Symptom score, SF, SC, feeling of complete evacuation, straining	Psyllium but not PBO associated with significant improvement vs baseline in symptom score but no significant difference between groups ($P = 0.095$); Psyllium associated with significant improvement in SC vs PBO at wk 8 ($P = 0.001$) but not weeks 4 and 12	No AEs observed

Table 6. (continued)

Reference	Methodologic score ^a	Intervention	Study design	Patients				Outcomes			
				N	Mean age, yrs	F/M	Diagnosis	Duration	Outcome parameters	Main efficacy results	Safety
Psyllium vs Na bicarbonate suppository vs psyllium + Na bicarbonate suppository											
Bouchoucha et al. (53)	1 (1,0,0)	Psyllium 3.6 g TID vs Na bicarbonate suppository QD vs psyllium 3.6 g TID + Na bicarbonate suppository QD	r, nb, co	20	51	16/4	Constipation (self-assessed; n = 20) and healthy controls (n = 20)	2 wks × 3	CTT, symptom self-assessment and physician assessment; SF, % of hard stools, incomplete evacuation	CTT decreased in all 3 treatment groups vs baseline but significantly more with suppository alone vs psyllium or suppository + psyllium (pts + controls); Psyllium alone had no effect on clinical parameters vs baseline	Not reported
Psyllium vs prunes											
Attaluri et al. (44)	3 (2,0,1)	Psyllium 11 g BID vs prunes 50 g BID (1:1)	r, sb, co	40	38	NR	CC—ROME III	3 wks × 2	CSBMs (primary), global constipation symptom score, SC, straining	Mean CSBMs/wk significantly higher with prune vs psyllium (3.5 vs 2.8; <i>P</i> = 0.006); Stool consistency score higher with prune (3.2 vs 2.8; <i>P</i> = 0.02); mean straining scores were similar; No of CSBMs/week in the psyllium group vs baseline (mean ± SE) 1.6 ± 0.2 vs 2.8 ± 0.2 <i>P</i> = 0.001	Palatability, satiety, postprandial fullness, and bloating were similar

Table 6. (continued)

Reference	Methodologic score ^a	Intervention	Study design	Patients				Outcomes			
				N	Mean age, yrs	F/M	Diagnosis	Duration	Outcome parameters	Main efficacy results	Safety
Psyllium vs mango											
Venancio et al. (45)	2 (1,0,1)	Psyllium 5 g/d vs mango 300 g/d (1:1)	r	36	24–29	25/11	CC—ROME III	4 wks	Evacuation (primary; difference from ideal [Bristol score = 4]; Agachan score	Mango ($P = 0.003$), but not psyllium, significantly improved evacuation category from baseline; Mango significantly improved evacuation category vs fiber ($P = 0.0269$); No significant difference between groups for Agachan score	No AEs occurred
Psyllium vs lactulose											
Quah et al. (55)	3 (2,0,1)	Psyllium 3.5 g BID vs lactulose 10–30 mL BID (1:1)	r, co	50	50	34/16	CC—ROME II	4 wks × 2	SF, SC, EOE	SF (7.3 vs 5.5; $P = 0.001$) and SC score (3.4 vs 2.9; $P = 0.018$) significantly greater with lactulose vs psyllium; No significant difference between treatments for EOE score	No significant difference in AEs between groups
Inulin vs placebo											
Micka et al. (4)	5 (2,2,1)	Inulin 12 g/d vs maltodextrin 12 g/d (PBO)	r, db, pc, co	44		33/11	CC (2–3 BMs/wk × 6 mo)	4 wks × 2	SF, SC, symptoms	Significantly greater SF with inulin vs PBO (4.0 vs 3.0/wk; $P = 0.038$); No significant difference between treatments for SC or straining	Significantly more flatulence with inulin vs PBO ($P < 0.001$)

Table 6. (continued)

Reference	Methodologic score ^a	Intervention	Study design	Patients					Outcomes			
				N	Mean age, yrs	F/M	Diagnosis	Duration	Outcome parameters	Main efficacy results	Safety	
Marteau et al. (57)	4 (1,2,1)	Inulin 15 g/d vs maltodextrin 15 g/d (PBO)	r, db, pc, pg	50	57	44/6	Constipation—ROME	4 wks	Microflora (primary); symptoms, BMs	No difference in SF or SC vs PBO; Significant increase in no. of pts with >1 BM/day and improvement in defecation difficulties vs baseline in inulin group but not PBO group (<i>P</i> < 0.01)	Flatulence significantly more frequent in inulin group vs PBO (<i>P</i> < 0.01)	
Polydextrose vs placebo												
Duncan et al. (58)	5 (2,2,1)	Polydextrose (8 or 12 g/d) vs PBO (1:1:1)	r, db, pc, pg	119	29–47	111/8	CC (CCCS 8–20 and criteria for constipation)	4 wks	Whole GI transit time (primary); SBMs; symptoms	No significant difference between groups in whole GI transit time; No difference in SBMs between treatment groups; Significant improvement with polydextrose in some symptoms (global score 8 g/d vs PBO; <i>P</i> = 0.018; abdominal subdomain score 8 g/d vs PBO; <i>P</i> = 0.039)	No difference between treatment groups	
Ibarra et al. (59)	5 (2,2,1)	Polydextrose (4, 8, 12 g/d) vs PBO (1:1:1:1)	r, db, pc, pg	192	43	133/59	CC—ROME III	2 wks PBO run-in + 2 wks	CTT (primary); symptoms; BMs	No significant difference between groups for CTT and most symptoms; Significant increase in BM frequency with 12 g polydextrose vs PBO (<i>P</i> = 0.017)	Mild to moderate GI symptoms with polydextrose	

Table 6. (continued)

Reference	Methodologic score ^a	Intervention	Study design	Patients			Diagnosis	Duration	Outcome parameters	Main efficacy results	Safety
				N	Mean age, yrs	F/M					
Mixed fiber											
Mixed fiber vs psyllium											
Erdogan et al. (60)	5 (2,2,1)	Mixed fiber (SupraFiber) 5 g BID vs psyllium 5 g BID vs PBO (1:1)	r, db	72	43	66/6	CC—ROME III	4 wks	CSBMs (primary), SC, symptoms	Both treatments increased CSBMs vs baseline with no difference between groups; Both treatments improved SC with no difference between groups	Flatulence was improved more in mixed fiber group ($P = 0.01$)

AE, adverse event; BID, twice daily; BM, bowel movement; CCGS, Cleveland Clinic Constipation Score; co, crossover; CSBM, complete spontaneous bowel movement; CTT, colonic transit time; db, double blind; EOE, ease of evacuation; F/M, female/male; GI, gastrointestinal; nb, nonblind; NR, not reported; PBO, placebo; pc, placebo controlled; pg, parallel group; pls, patients; QD, once daily; QoL, quality of life; r, randomized; sb, single blind; SBM, spontaneous bowel movement; SE, standard error; SF, stool frequency; T2DM, type-2 diabetes mellitus; TID, 3 times daily.

^aTotal score with individual scores for randomization, blinding, and statement on withdrawals in parentheses.

grade-A recommendation, psyllium had level II evidence with a grade-B recommendation, and stimulant laxatives, magnesium hydroxide (milk of magnesia), and docusate all had level III evidence with grade C recommendations. Fruit-based laxatives and foods with prebiotics were not assessed (14). In general, the spectrum of OTC products that have been tested has increased and the quality of evidence has improved. Today, there are a greater number of placebo-controlled trials of higher quality, but there remains considerable variability in trial design. Definitions of constipation have become more standardized, with most studies in this analysis using ROME-based criteria (30/41 [73%]). The remainder did not use these criteria, which limited their quality. The biggest hinderance to evaluating these studies is a lack of consistent outcome measures between trials. Stool frequency (CSBMs, SBMs, or BMs) and stool consistency were the most common outcomes used, but the manner in which these were defined, measured, and the intervals of measurement varied.

The current FDA responder criteria for chronic idiopathic constipation trials are based on a CSBM weekly response (i.e., ≥ 3 CSBMs/week plus an increase of ≥ 1 CSBM/week from baseline). These were not used in any of the studies. Other measures of outcome included response rates (varying definitions), ease of defecation, straining, symptoms, transit times, and patient-reported outcomes (PROs) such as the Patient Global Impression of Change, the Patient Assessment of Constipation Symptoms, and the Patient Assessment of Constipation-Quality of Life. It should be noted that PRO measures have become increasingly important clinical tools, and the US FDA developed a draft guidance statement on their use for GI conditions (65). Another limitation was that there were only single studies available for many of the treatment categories. Consequently, the lack of confirmatory studies resulted in both a lower level of evidence category and a lower grade of recommendation. Most studies were of very short duration (typically 4 weeks) except for PEG studies, which ranged up to 6 months. Given that constipation is often a chronic problem, it behooves all investigators to consider longer-term (3- to 12-month) studies to provide confidence regarding durability of response. If the indication of an OTC product is for occasional and/or short-term use, then a 4- to 6-week study design may be appropriate, with stricter appraisal of changes in daily stool habits, ideally using validated paper form stool diary (66) or a recently validated electronic constipation stool APP diary (67).

Overall, PEG was the OTC laxative with the most robust clinical evidence (i.e., 3 placebo-controlled trials with quality scores of 5, 5, and 4), and it and senna are the only OTC agents with level I evidence and grade A recommendations. For PEG, this recommendation remains unchanged with newer studies providing further evidence supporting its use as a first-line treatment for chronic idiopathic constipation. PEG is highly effective with similar or superior efficacy to other OTC and prescription therapies and is well tolerated with long-term administration. In comparison studies, adverse events associated with PEG were similar in pattern and frequency to those of lactulose (25,26) and tegaserod (increased rates of headaches with tegaserod) (27) and lower in frequency compared with prucalopride (68% vs 85%) (28,29) and naloxegol (17% vs 24%) (30).

Psyllium and SupraFiber both have level II evidence and grade B recommendations. Despite the addition of 9 new studies, psyllium seems to have only modest efficacy and in head-to-head trials seems inferior to some other agents (e.g., PEG, lactulose, and prunes). Thus, its level of evidence and grade recommendation remains unchanged. Other fiber laxatives (polydextrose,

Table 7. Miscellaneous agents in the treatment of constipation

Reference	Methodologic score ^a	Intervention	Study design	Patients				Outcomes			
				N	Mean age, yrs	F/M	Diagnosis	Duration	Outcome parameters	Main efficacy results	Safety
Constipation in chronic kidney disease											
Shimada et al. (61)	5 (2,2,1)	Polydextrose 10 g QD vs PBO (1:1)	r, tb, pc	50	51–79	16/34	Hemodialysis; ≥1 laxative tablet for >3 mo	8 wks	SF (primary), SC, abdominal pain, bloating	Polydextrose associated with significant increase in SF/wk vs PBO (8.5 vs 5.0; <i>P</i> < 0.05); No significant difference in abdominal distension	Clinical biochemistry values did not change
Ramos et al. (62)	5 (2,2,1)	Flaxseed oil 2 mL/d vs olive oil 2 mL/d vs mineral oil 2 mL/d (control; 1:1:1)	r, db	50	51	21/29	Hemodialysis pts with constipation—ROME III	4 wks	Frequency of symptoms (ROME III score); SC, SF	All groups significantly reduced symptom scores from baseline; SF and SC only improved from baseline with flaxseed oil (no <i>P</i> values reported)	All well tolerated; 5 pts discontinued due to oil taste (<i>n</i> = 2), persistent constipation (<i>n</i> = 2), diarrhea (<i>n</i> = 1)
Meksawan et al. (63)	4 (1,2,1)	Fructo-oligosaccharide 20 g/d vs PBO (1:1)	r, db, pc, co	13	71	5/8	CC—ROME II and ESRD/CAPD (≥50 yrs)	30 d	BMs, colonic transit	BM/wk significantly increased vs PBO 10.5 vs 6.2 (<i>P</i> < 0.005); Significant increase in colonic transit with fructo-oligosaccharide (<i>P</i> = 0.0028)	Mild flatulence and abdominal discomfort with fructo-oligosaccharide
Miscellaneous probiotic/synbiotic											
Psyllium, inulin, and probiotics vs placebo											
Cudmore et al. (64)	5 (2,2,1)	Lepicol [®] (psyllium, inulin, probiotics) 5 g BID vs PBO 5 g BID (1:1)	r, db, pc, pg	69	42–45	64/5	CC—ROME III	4 wks	Increase in BMs of 1.5/wk; SC	Significant improvement in BM/wk vs PBO in weeks 1 and 2 but not weeks 3 and 4; No difference in SC between groups	No difference between groups

Table 7. (continued)

Reference	Methodologic score ^a	Intervention	Study design	Patients				Outcomes			
				N	Mean age, yrs	F/M	Diagnosis	Duration	Outcome parameters	Main efficacy results	Safety
UG1601 (inulin, lactitol, aloe vera) vs placebo											
Chu et al. (19)	5 (2,2,1)	UG1601 (inulin, lactitol, aloe vera) 13 g QD vs PBO 13 g QD (1:1)	r, db, pc, pg	40	24–25	30/10	Constipation (ROME)	4 wks	SF score, symptoms (SC, incomplete evacuation time for evacuation, flatulence)	No significant difference for any parameter	Not reported
Oligofructose vs placebo											
Buddington et al. (36)	4 (1,2,1)	Oligofructose 15 g/d vs maltodextrin 5–15 g/d (PBO; 1:1)	r, db, pg	97	33–34	76/23	Constipation (1–3 BMs/wk) and low fiber intake	16 wks	SF (primary); SC	SF significantly higher with oligofructose (<i>P</i> = 0.023) with benefit especially in pts with lowest fiber intake; No difference in SC	Not reported

BID, twice daily; BM, bowel movement; CAPD, continuous ambulatory peritoneal dialysis; CC, chronic constipation; co, crossover; db, double blind; ERSD, end-stage renal disease; F/M, female/male; PBO, placebo; pc, placebo controlled; pg, parallel group; pts, patients; QD, once daily; r, randomized; SC, stool consistency; SF, stool frequency; tb, triple blind.

^aTotal score with individual scores for randomization, blinding, and statement on withdrawals in parentheses.

inulin, and insoluble fibers) have insufficient evidence to recommend for or against their use in the treatment of constipation.

Magnesium-containing agents seem to be effective. Four high-quality placebo-controlled trials demonstrated the efficacy of both magnesium-containing mineral water and, more recently, magnesium oxide, resulting in level I evidence and a grade B recommendation. However, there was a lack of standardization of magnesium content in the evaluated preparations. The starting dose of magnesium oxide was 1.5 g daily, but 53.3% of subjects required a dose reduction during the 4-week trial. Allowance for dose reduction resulted in a lack of any withdrawals. No further studies evaluating magnesium hydroxide (milk of magnesia) were identified. More recent studies using stimulant laxatives (bisacodyl, sodium picosulfate, and senna) have yielded improved levels of evidence and grade recommendations. Although all 3 had level III evidence with grade C recommendations in the previous systematic review, the current review identified level I evidence with grade B recommendations for both bisacodyl and sodium picosulfate and level I evidence and a grade A recommendation for senna. However, diphenylmethane derivatives are associated with a significantly greater incidence of GI adverse events (diarrhea and abdominal pain) which may limit their clinical utility. Senna was tested in 2 randomized placebo-controlled studies with both yielding improvements in constipation. The most recent study with senna used a starting dose of 1 g/d, and although it was significantly more efficacious than placebo and comparable with magnesium oxide, dose reductions were required in 83.3% of subjects. Thus, whether a smaller dose of this product is as effective and better tolerated, especially for the occasional constipation, merits further study. Of the fruit-based laxatives evaluated, kiwi was the only one with Level I evidence (i.e., 2 randomized controlled trials), whereas mango, prunes, and ficus all had level II evidence (1 trial each). These products were efficacious (grade B recommendation), but because of the few studies with limited numbers of patients, they were afforded lower Grade recommendations.

Despite docusate's wide use for constipation, there have been no new studies evaluating its efficacy. In the previous review, docusate had level III evidence and a grade C recommendation, based on trials that found docusate to be no more effective than placebo and significantly inferior to psyllium (14). Given the current literature or lack thereof, we are unable to provide a recommendation for docusate.

Overall, the OTC products analyzed in this review seemed to be safe and well tolerated, with no reports of serious adverse events, although some studies failed to report any adverse events. GI symptoms (abdominal pain, cramps, bloating, diarrhea, and nausea) were the most common adverse events reported with a variable incidence for each product, and headache was the chief non-GI adverse event reported.

The limitations of our systematic review include that only studies published in the English literature were assessed, and given that constipation is a common global problem, it is possible that there are some remedies that have been tested and published in other languages that have been excluded in this review. We did exclude studies of less than 4 weeks' duration because we believed that a product that is likely to benefit a chronic condition should demonstrate both efficacy and safety over at least a one-month period. Although there are several methods of categorizing the basis of evidence for drug efficacy and safety, we chose the USPSTF criteria to provide meaningful comparative data with our previous analysis (14).

In conclusion, PEG and senna are the only OTC laxatives with level I evidence and grade A recommendations for the treatment

of constipation, although PEG is the only one supported by both short- and long-term studies. Other OTC laxatives with a grade B recommendation include psyllium, SupraFiber, magnesium-rich water, magnesium oxide, diphenylmethane stimulants (bisacodyl and sodium picosulfate), fruit-based laxatives (kiwi, mango, prunes, and ficus), and yogurt plus galacto-oligosaccharide, prunes, and linseed oil. There was insufficient evidence (grade I) for polydextrose, inulin, and fructo-oligosaccharide. For these and other alternative products, there is a clear need for more rigorous, high-quality studies using standardized endpoints. Docusate lacks well-controlled trials demonstrating its efficacy and has poor evidence to support its use in clinical practice.

CONFLICTS OF INTEREST

Guarantor of the article: Darren M. Brenner, MD.

Specific author contributions: S.S.C.R. and D.M.B. conceived the project and developed the search criteria and parameters for the systematic review, reviewed the literature independently, and provided independent recommendations regarding the quality of studies, strength of evidence, and recommendation grading. Both authors equally contributed to the writing of the manuscript and provided extensive revisions.

Financial support: Medical writing support and literature search was provided by BioCentric, Inc. The development of this manuscript was supported by funding from the Bayer US LLC.

Potential competing interests: SSCR has served as an advisory board member and consultant for Bayer Pharmaceuticals and previously received unrestricted research grant support from Sun Sweets corporation and California dried plums grower's association. DMB has received consulting fees from Bayer Pharmaceuticals and is supported in research by an unrestricted gift from the Irene D. Pritzker Foundation.

Study Highlights

WHAT IS KNOWN

- ✓ Chronic constipation is a common condition that significantly affects quality of life.
- ✓ Approximately 40% of individuals with constipation self-treat with over-the-counter (OTC) laxatives.
- ✓ Multiple classes of OTC therapies are available for treating chronic constipation.
- ✓ Polyethylene glycol was the only OTC therapy to receive a strong recommendation based on high levels of evidence in a previous systematic review published in 2005.

WHAT IS NEW HERE

- ✓ The spectrum of OTC products that have been tested has increased and the quality of evidence has improved.
- ✓ There is now good evidence based on high-quality trials supporting the use of polyethylene glycol and senna for constipation.
- ✓ Moderate evidence supports the use of psyllium, fruits, magnesium-containing compounds, bisacodyl, and sodium picosulfate for the treatment of constipation.
- ✓ There is a clear need for more rigorous, high-quality studies using standardized endpoints.

REFERENCES

- Pare P, Ferrazzi S, Thompson WG, et al. An epidemiological survey of constipation in Canada: Definitions, rates, demographics, and predictors of health care seeking. *Am J Gastroenterol* 2001;96:3130–7.
- Higgins PD, Johanson JF. Epidemiology of constipation in North America: A systematic review. *Am J Gastroenterol* 2004;99(4):750–9.
- Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: Systematic review and meta-analysis. *Am J Gastroenterol* 2011;106:1582–91.
- Pinto Sanchez MI, Bercik P. Epidemiology and burden of chronic constipation. *Can J Gastroenterol* 2011;25(Suppl B):11b–15b.
- Cai Q, Buono JL, Spalding WM, et al. Healthcare costs among patients with chronic constipation: A retrospective claims analysis in a commercially insured population. *J Med Econ* 2014;17:148–58.
- Werth BL, Williams KA, Fisher MJ, et al. Defining constipation to estimate its prevalence in the community: Results from a national survey. *BMC Gastroenterol* 2019;19:75.
- Rao SSC, Rattanakovit K, Pancharatrakul T. Diagnosis and management of chronic constipation in adults. *Nat Rev Gastroenterol Hepatol* 2016;13:295–305.
- Rao SSC, Camilleri M. Approach to the patient with constipation. In: Podolsky DK, Camilleri M, Fitz JG, et al (eds). *Yamada's Textbook of Gastroenterology*, 6th edn. Wiley-Blackwell: Hoboken, NJ; 2016, pp 757–72.
- Belsey J, Greenfield S, Candy D, et al. Systematic review: Impact of constipation on quality of life in adults and children. *Aliment Pharmacol Ther* 2010;31(9):938–49.
- Rao SSC, Seaton K, Miller MJ, et al. Psychological profiles and quality of life differ between patients with dyssynergia and those with slow transit constipation. *J Psychosomatic Res* 2007;63:441–9.
- Wald A, Scarpignato C, Mueller-Lissner S, et al. A multinational survey of prevalence and patterns of laxative use among adults with self-defined constipation. *Aliment Pharmacol Ther* 2008;28:917–30.
- Consumer Health Products Association. OTC Sales by Category 2015–2019 (<https://www.chpa.org/OTCsCategory.aspx>). Accessed Sept 8 2019.
- US Bureau of Labor Statistics. CPI Inflation Calculator (https://www.bls.gov/data/inflation_calculator.htm). Accessed September 10 2020.
- Ramkumar D, Rao SSC. Efficacy and safety of traditional medical therapies for chronic constipation: Systematic review. *Am J Gastroenterol* 2005;100:936–71.
- US Preventive Services Task Force. Grade definitions (<https://www.uspreventiveservicestaskforce.org/uspstf/grade-definitions>) (2018). Accessed September 29 2020.
- Morishita D, Tomita T, Mori S, et al. Senna versus magnesium oxide for the treatment of chronic constipation: A randomized, placebo-controlled trial. *Am J Gastroenterol* 2021;116(1):152–61.
- Tack J, Müller-Lissner S. Treatment of chronic constipation: Current pharmacologic approaches and future directions. *Clin Gastroenterol Hepatol* 2009;7:502–8.
- Andrews CN, Storr M. The pathophysiology of chronic constipation. *Can J Gastroenterol* 2011;25(Suppl B):16B–21B.
- Chu JR, Kang SY, Kim SE, et al. Prebiotic UG1601 mitigates constipation-related events in association with gut microbiota: A randomized placebo-controlled intervention study. *World J Gastroenterol* 2019;25:6129–44.
- Pelham RW, Nix LC, Chavira RE, et al. Clinical trial: Single- and multiple-dose pharmacokinetics of polyethylene glycol (PEG-3350) in healthy young and elderly subjects. *Aliment Pharmacol Ther* 2008;28:256–65.
- DiPalma JA, Cleveland MbV, McGowan J, et al. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. *Am J Gastroenterol* 2007;102:1436–41.
- DiPalma JA, Cleveland MB, McGowan J, et al. A comparison of polyethylene glycol laxative and placebo for relief of constipation from constipating medications. *South Med J* 2007;100:1085–90.
- Zangaglia R, Martignoni E, Glorioso M, et al. Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study. *Mov Disord* 2007;22:1239–44.
- Seinelä L, Sairanen U, Laine T, et al. Comparison of polyethylene glycol with and without electrolytes in the treatment of constipation in elderly institutionalized patients. *Drugs Aging* 2009;26:703–13.
- Chassagne P, Ducrotte P, Garnier P, et al. Tolerance and long-term efficacy of polyethylene glycol 4000 (Forlax[®]) compared to lactulose in elderly patients with chronic constipation. *J Nutr Health Aging* 2017;21:429–39.
- Piche T, Dapoigny M. Comparative efficacy and safety of lactulose plus paraffin vs polyethylene glycol in functional constipation: A randomized clinical study. *United Eur Gastroenterol J* 2020;8:923–32.
- DiPalma JA, Cleveland MbV, McGowan J, et al. A randomized, multicenter comparison of polyethylene glycol laxative and tegaserod in treatment of patients with chronic constipation. *Am J Gastroenterol* 2007;102:1964–71.
- Cinca R, Chera D, Gruss H-J, et al. Randomised clinical trial: macrogol/PEG 3350+electrolytes versus prucalopride in the treatment of chronic constipation—a comparison in a controlled environment. *Aliment Pharmacol Ther* 2013;37:876–86.
- ClinicalTrials.gov. Comparator study of PEG 3350 versus prucalopride in females with chronic constipation (<https://clinicaltrials.gov/ct2/show/NCT01251822>) (2012). Accessed October 19, 2020.
- Brenner DM, Hu Y, Datto C, et al. A randomized, multicenter, prospective, crossover, open-label study of factors associated with patient preferences for naloxegol or PEG 3350 for opioid-induced constipation. *Am J Gastroenterol* 2019;114:954–63.
- Kamm MA, Mueller-Lissner S, Wald A, et al. Oral bisacodyl is effective and well-tolerated in patients with chronic constipation. *Clin Gastroenterol Hepatol* 2011;9:57–83.
- Mueller-Lissner S, Kamm MA, Wald A, et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation. *Am J Gastroenterol* 2010;105:897–903.
- Kienzle-Horn S, Vix J-M, Schuijt C, et al. Comparison of bisacodyl and sodium picosulfate in the treatment of chronic constipation. *Curr Med Res Opin* 2007;23:691–9.
- Soufi-Afshar I, Moghadamnia A, Bijani A, et al. Comparison of pyridostigmine and bisacodyl in the treatment of refractory chronic constipation. *Caspian J Intern* 2015;7:19–24.
- Zhong LLD, Cheng C-w, Kun W, et al. Efficacy of MaZiRenWan, a Chinese herbal medicine, in patients with functional constipation in a randomized controlled trial. *Clin Gastroenterol Hepatol* 2019;17:1303–10.
- Buddington RK, Kapadia C, Neumer F, et al. Oligofructose provides laxation for irregularity associated with low fiber intake. *Nutrients* 2017;9:1372.
- Naumann J, Sadaghiani C, Alt F, et al. Effects of sulfate-rich mineral water on functional constipation: A double-blind, randomized, placebo-controlled study. *Forsch Komplementmed* 2016;23(6):356–63.
- Dupont C, Campagne A, Constant F. Efficacy and safety of magnesium sulfate-rich natural mineral water for patients with functional constipation. *Clin Gastroenterol Hepatol* 2014;12:1280–7.
- Bothe G, Cob A, Auinger A. Efficacy and safety of a natural mineral water rich in magnesium and sulphate for bowel function: A double-blind, randomized, placebo-controlled study. *Eur J Nutr* 2017;56:491–9.
- Williams BA, Mikkelsen D, Flanagan BM, et al. “Dietary fiber”: Moving beyond the “soluble/insoluble” classification for monogastric nutrition, with an emphasis on humans and pigs. *J Anim Sci Biotech* 2019;10:45.
- Wilkinson-Smith V, Dellschaft N, Ansell J, et al. Mechanisms underlying effects of kiwifruit on intestinal function shown by MRI in healthy volunteers. *Aliment Pharmacol Ther* 2019;59:759–68.
- Ansell J, Butts CA, Paturi G, et al. Kiwifruit-derived supplements increase stool frequency in healthy adults: A randomized, double-blind, placebo-controlled study. *Nutr Res* 2015;35:401–8.
- Udani JK, Bloom DW. Effects of kivia powder on gut health in patients with occasional constipation: A randomized, double-blind, placebo-controlled study. *Nutr J* 2013;12:78.
- Attaluri A, Donahoe R, Valesin J, et al. Randomised clinical trial: Dried plums (prunes) vs. psyllium for constipation. *Aliment Pharmacol Ther* 2011;33:822–8.
- Venancio VP, Kim H, Sirven MA, et al. Polyphenol-rich mango (*Mangifera indica* L.) ameliorate functional constipation symptoms in humans beyond equivalent amount of fiber. *Mol Nutr Food Res* 2018;62:1701034.
- Baek HI, Ha KC, Kim HM, et al. Randomized, double-blind, placebo controlled trial of *Ficus carica* paste for the management of functional constipation. *Asia Pac J Clin Nutr* 2016;25:487–96.
- Malaguarnera M, Vacante M, Condorelli G, et al. Probiotics and prebiotics in the management of constipation in the elderly. *Acta Med Mediterranea* 2013;29:791–8.
- Dimidi E, Christodoulides S, Scott SM, et al. Mechanisms of action of probiotics and the gastrointestinal microbiota on gut motility and constipation. *Adv Nutr* 2017;8:484–94.

49. Sairanen U, Piirainen L, Nevala R, et al. Yoghurt containing galacto-oligosaccharides, prunes and linseed reduces the severity of mild constipation in elderly subjects. *Eur J Clin Nutr* 2007;61:1423–8.
50. Hongisto SM, Paajanen L, Saxelin M, et al. A combination of fibre-rich rye bread and yoghurt containing *Lactobacillus* GG improves bowel function in women with self-reported constipation. *Eur J Clin Nutr* 2006;60:319–24.
51. Soltanian N, Janghorbani M. Effect of flaxseed or psyllium vs. placebo on management of constipation, weight, glycemia, and lipids: A randomized trial in constipated patients with type 2 diabetes. *Clin Nutr ESPEN* 2019;29:41–8.
52. Soltanian N, Janghorbani M, Adibi P. Effects of psyllium vs. placebo on constipation, weight, glycemia, and lipids: A randomized trial in patients with type 2 diabetes and chronic constipation. *Compl Ther Med* 2018;40:1–7.
53. Bouchoucha M, Faye A, Savarieau B, et al. Effect of an oral bulking agent and a rectal laxative administered alone or in combination for the treatment of constipation. *Gastroenterol Clin Biol* 2004;28:438–43.
54. Cheng J, Tennila J, Stenman L, et al. Influence of lactitol and psyllium on bowel function in constipated Indian volunteers: A randomized, controlled trial. *Nutrients* 2019;11:1130.
55. Quah HM, Ooi BS, Seow-Choen F, et al. Prospective randomized crossover trial comparing fibre with lactulose in the treatment of idiopathic chronic constipation. *Tech Coloproctol* 2005;10:111–4.
56. Micka A, Siepelmeyer A, Holz A, et al. Effect of consumption of chicory inulin on bowel function in healthy subjects with constipation: A randomized, double-blind, placebo-controlled trial. *Int J Food Sci Nutr* 2017;68:82–9.
57. Marteau P, Jacobs H, Cazaubiel M, et al. Effects of chicory inulin in constipated elderly people: A double-blind controlled trial. *Int J Food Sci Nutr* 2011;62:164–70.
58. Duncan PI, Enters-Weijnen CF, Emami N, et al. Short-term daily intake of polydextrose fiber does not shorten intestinal transit time in constipated adults: A randomized controlled trial. *Nutrients* 2018;10:920.
59. Ibarra A, Pelipiyagina T, Rueffer M, et al. Efficacy of polydextrose supplementation on colonic transit time, bowel movements, and gastrointestinal symptoms in adults: A double-blind, randomized, placebo-controlled trial. *Nutrients* 2019;11:439.
60. Erdogan A, Rao S, Thiruvaiyaru D, et al. Randomized clinical trial: Soluble/insoluble fiber or psyllium for chronic constipation. *Aliment Pharmacol Ther* 2016;44:35–44.
61. Shimada M, Nagano N, Goto S, et al. Effect of polydextrose intake on constipation in Japanese dialysis patients: A triple-blind, randomized, controlled trial. *J Nutr Sci Vitaminol* 2015;61:345–53.
62. Ramos CI, de Lima AFA, Grilli DG, et al. The short-term effects of olive oil and flaxseed oil for the treatment of constipation in hemodialysis patients. *J Ren Nutr* 2015;25:50–6.
63. Meksawan K, Chaotrakul C, Leephorn N, et al. Effects of fructo-oligosaccharide supplementation on constipation in elderly continuous ambulatory peritoneal dialysis patients. *Peritoneal Dial Internat* 2016;35:60–6.
64. Cudmore S, Doolan A, Lacey S, et al. A randomized, double-blind, placebo-controlled clinical study: The effects of a synbiotic, lepicol, in adults with chronic, functional constipation. *Internat J Food Sci Nutr* 2017;68:366–7.
65. FDA. Guidance for industry irritable bowel syndrome—clinical evaluation of drugs for treatment (<https://www.fda.gov/media/78622/download>) (2012). Accessed September 10, 2020.
66. Meduri K, Brown CK, Attaluri A, et al. Validation of a prospective stool diary for assessment of constipation. *Neurogastroenterol Motil* 2011;23(Suppl 1):12.
67. Yan Y, Jimenez E, Sharma A, et al. How useful is constipation stool APP compared to paper stool diary-randomized study of constipation and healthy subjects. *Gastroenterology* 2020;158(6 Suppl 1):S-400.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.